GlassScriptPhysician profile
Yogesh Kumar Trehan
NPI 1255372769
$10,145.85
in general payments reported to CMS, 2019-2025
36 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $1,026 · 2021: $981 · 2022: $639 · 2023: $4,572 · 2024: $1,100 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,550 · Food and Beverage: $1,957 · Travel and Lodging: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,550.00 |
| Food and Beverage | $1,956.68 |
| Travel and Lodging | $1,288.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,757.14 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $672.98 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Amarin Pharma, INC. | $557.56 | 2020-2021 | |
| Glaxosmithkline, LLC. | $436.81 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $296.92 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $289.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $281.36 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.51 | 2019-2025 | Ofev, Jardiance |
| Allergan, INC. | $166.12 | 2019-2020 | |
| Pfizer INC. | $155.10 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $105.25 | 2019-2022 | |
| Astellas Pharma US INC | $104.00 | 2019-2023 | Veozah |
| Biohaven Pharmaceuticals, INC. | $97.05 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $95.23 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.12 | 2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yogesh Trehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.